Stocktoria
Beyond Air, Inc. XAIR
Beyond Air, Inc. (XAIR) earns a Piotroski F-score of 5/9 (mixed financial health). It does not currently pay a dividend. FY2026 revenue was $7.7M at a -433.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XAIR | Beyond Air, Inc. | 5/9 | — | — | — |
| IVF | INVO Fertility, Inc. | 4/9 | -19.01 | — | — |
| NSPR | InspireMD, Inc. | 3/9 | -10.12 | — | — |
| NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | 5/9 | -19.57 | — | — |
| MDNC | Medinotec Inc. | 5/9 | — | 74 | — |
| WOK | WORK Medical Technology Group LTD | 4/9 | — | — | -14.4% |
| PSTV | PLUS THERAPEUTICS, INC. | 3/9 | — | — | — |
About Beyond Air, Inc.
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
FAQ
Is XAIR financially healthy?
Beyond Air, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).
Does XAIR pay a dividend?
No, Beyond Air, Inc. does not currently pay a dividend.
How profitable is XAIR?
In FY2026, Beyond Air, Inc. had a net margin of -433.0% and a return on equity of -535.4%.
What is the analyst price target for XAIR?
The average Wall-Street price target for Beyond Air, Inc. is $8.00, about 32.2% above the recent price, from 2 analysts (consensus: buy).
Is XAIR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Beyond Air, Inc.: a Piotroski F-score of 5/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.